SCI Pharmtech reports Sep revenue of NT$163.4M
SCI Pharmtech Inc. reported September revenue of NT$163,394,000 versus NT$122,806,000 a year earlier, with Jan-Sep revenue at NT$1,151,808,000 versus NT$988,248,000.
SCI Pharmtech Inc. reported revenue of NT$163,394,000 for 2026, compared with NT$122,806,000 in 2025, according to Taiwan Stock Exchange figures in New Taiwan dollars. For Jan-Sep, revenue was NT$1,151,808,000 in 2026 versus NT$988,248,000 in 2025.